Clinical Trial Update: The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

View source ↗

Summary

A real-world study assessing AK104 in combination with transarterial chemoembolization (TACE) for patients with resectable hepatocellular carcinoma at high risk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Resectable Hepatocellular Carcinoma With High Risk of Recurrence | Status: RECRUITING